Concepedia

Publication | Open Access

Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

DOIFull Paper Access

151

Citations

23

References

2014

Year

Maxime Ronot, Mohamed Bouattour, Johanna Wassermann, Onorina Bruno, Chantal Dreyer, Béatrice Larroque, Laurent Castéra, Valérie Vilgrain, Jacques Belghiti, Éric Raymond,
The Oncologist

Abstract

Choi, EASL, and mRECIST criteria appear more appropriate than RECIST 1.1 to identify responders with long survival among advanced HCC patients benefiting from sorafenib.

References

YearCitations

Page 1